GO:0071880 adenylate cyclase-activating adrenergic receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071880 describes a biological process in which an adrenergic receptor on the cell surface binds a ligand and activates adenylate cyclase, raising cyclic AMP (cAMP) and regulating downstream cellular responses.
• The pathway is initiated by catecholamines such as norepinephrine and epinephrine acting on adrenergic receptors, and it converges on cAMP-dependent effectors including PKA and CREB [1,4].
• Key molecular players include ADRB1, ADRB2, ADRB3, GNAS, ADCY isoforms, PRKACA, and CREB1, with crosstalk from PACAP/VIP receptors in neuroendocrine systems [4,6,8].
• Experimental evidence links this pathway to circadian regulation, melatonin synthesis, adrenal medullary secretion, and neuropsychiatric drug responses [1,2,4,5].
• Dysregulation of adrenergic-cAMP signaling is implicated in cardiac, metabolic, and psychiatric conditions, making it a target for pharmacological and genetic studies [3,5].
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of GO:0071880 components in relevant cell types [1,2,4].
Description
GO:0071880, adenylate cyclase-activating adrenergic receptor signaling pathway, is a biological process that begins when an adrenergic receptor binds its ligand on the surface of a target cell and ends with regulation of a downstream cellular process. This pathway is a canonical example of G protein-coupled receptor (GPCR) signaling, in which receptor activation promotes the production of cyclic AMP (cAMP) by adenylate cyclase and subsequently modulates effectors such as protein kinase A (PKA) and the transcription factor CREB [1,4]. Researchers study this term because it integrates neurotransmitter and hormonal signals into changes in gene expression, secretion, and metabolism across neuronal, endocrine, and cardiac systems [1,2,4]. The pathway is experimentally tractable: adrenergic agonists can activate transcriptional activity in immortalized neuronal cells, and cAMP-CREB signaling controls melatonin synthesis in pinealocytes. In parallel, related adenylate cyclase-activating pathways involving PACAP and VIP receptors provide comparative insight into how cAMP signaling is organized in neuroendocrine tissues [6,8]. Because the pathway is defined by its initiating receptor class and its coupling to adenylate cyclase, it serves as a framework for understanding how adrenergic input is converted into cell-type-specific outputs [1,4].
adenylate cyclase-activating adrenergic receptor signaling pathway At A Glance
| GO ID | GO:0071880 |
|---|---|
| GO term | adenylate cyclase-activating adrenergic receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activation of adenylate cyclase activity by adrenergic receptor signaling pathway; adrenergic receptor, adenylate cyclase activating pathway; adrenergic receptor, adenylyl cyclase activating pathway |
| Major function | Couples adrenergic ligand binding to activation of adenylate cyclase and cAMP-dependent downstream regulation. |
| Pathway class | Adenylate cyclase-activating GPCR signaling pathway. |
| Initiating receptor | Adrenergic receptors on the target cell surface. |
| Key second messenger | Cyclic AMP (cAMP) produced by adenylate cyclase [1,4]. |
| Representative downstream effect | CREB phosphorylation and regulation of gene expression or secretion. |
What Is GO:0071880?
In simple terms, GO:0071880 is the process in which a signal molecule binds to an adrenergic receptor on the cell surface, and this receptor then switches on adenylate cyclase to make cAMP, which changes what the cell does next. More formally, it is an adenylate cyclase-activating G protein-coupled receptor signaling pathway initiated by ligand binding to an adrenergic receptor and ending with regulation of a downstream cellular process.
Why Is adenylate cyclase-activating adrenergic receptor signaling pathway Important in Cell Biology?
GO:0071880 matters because it is a central mechanism by which catecholamines and adrenergic drugs control neuronal, endocrine, and cardiac function, and because its dysregulation is linked to human disease and drug action [1,3,5]. Experimental work shows that adrenergic agonists can activate transcriptional activity in immortalized neuronal cells from the suprachiasmatic nucleus, linking this pathway to circadian biology. In pinealocytes, cAMP-CREB signaling downstream of adenylate cyclase-activating receptors controls melatonin synthesis, illustrating how the pathway converts receptor occupancy into a measurable physiological output. Network pharmacology studies of clozapine-induced cardiac arrest and aripiprazole in hyperprolactinemia highlight adrenergic and cAMP-related mechanisms as contributors to drug effects and adverse outcomes [3,5]. Comparative studies of PACAP and VIP receptors further show how adenylate cyclase-activating pathways are used across neuroendocrine systems [6,8].
• Controls cAMP production and downstream PKA/CREB signaling in response to adrenergic ligands [1,4].
• Regulates transcriptional programs in neuronal cells, including suprachiasmatic nucleus-derived cells.
• Drives melatonin synthesis in pinealocytes through CREB phosphorylation.
• Contributes to adrenal medullary chromaffin cell secretion mechanisms.
• Is implicated in cardiac effects of psychiatric drugs such as clozapine.
• Is relevant to hyperprolactinemia mechanisms explored for aripiprazole.
• Provides a comparative framework with PACAP/VIP adenylate cyclase-activating pathways [6,8].
• Offers druggable nodes (receptors, G proteins, adenylate cyclase) for pharmacological intervention [1,3,5].
• Supports research on learning and transmitter interactions via PACAP-related cAMP signaling.
• Enables CRISPR-based causal testing of pathway components in disease-relevant cell models [1,2,4].
What Happens During adenylate cyclase-activating adrenergic receptor signaling pathway?
Ligand binding and receptor activation
In simple terms: A signal molecule docks onto an adrenergic receptor, switching the receptor on.
The pathway begins when an adrenergic ligand binds to an adrenergic receptor on the surface of the target cell. This receptor belongs to the G protein-coupled receptor family, and its activation is the initiating event that defines GO:0071880. In experimental systems, adrenergic agonists can activate transcriptional activity in immortalized neuronal cells from the mouse suprachiasmatic nucleus, demonstrating that receptor activation is coupled to downstream gene regulation. Comparative studies of related adenylate cyclase-activating receptors, such as PACAP and VIP receptors in the pineal gland, show that ligand-receptor specificity shapes the downstream response.
G protein coupling and adenylate cyclase activation
In simple terms: The switched-on receptor turns on a helper protein that then activates an enzyme called adenylate cyclase.
Activated adrenergic receptors couple to G proteins and stimulate adenylate cyclase, the enzyme that produces cAMP. This step is the defining biochemical feature of the term: an adenylate cyclase-activating GPCR signaling pathway. In pinealocytes, adenylate cyclase-activating receptors are pharmacologically and molecularly characterized, and their activation leads to cAMP accumulation. The same logic applies to PACAP receptor signaling, where receptor activation elevates cAMP and triggers downstream effects.
cAMP accumulation and PKA/CREB signaling
In simple terms: The enzyme makes a small messenger molecule that activates proteins which change gene activity.
The cAMP produced by adenylate cyclase acts as a second messenger that activates downstream effectors, including protein kinase A and the transcription factor CREB. In rat pinealocytes, control of CREB phosphorylation is required for induction of melatonin synthesis, directly linking cAMP-dependent signaling to a physiological output. This step illustrates how GO:0071880 ends with regulation of a downstream cellular process, as stated in the definition [1,4].
Downstream cellular outputs and crosstalk
In simple terms: The signal changes what the cell does, such as secreting a hormone or altering gene expression.
Downstream outputs of adenylate cyclase-activating adrenergic signaling include changes in transcription, secretion, and neuronal function [1,2,4]. In adrenal medullary chromaffin cells, muscarine, PACAP, and angiotensin II evoke secretion with a focus on TRPC channels, showing how cAMP-linked pathways intersect with ion channel-dependent secretion. PACAP action on passive avoidance learning involves transmitter interactions, indicating that adenylate cyclase-activating pathways can modulate behaviorally relevant circuits. Network pharmacology studies of clozapine and aripiprazole further suggest that adrenergic and cAMP-related mechanisms contribute to drug effects in cardiac and prolactin-related biology [3,5].
Key Genes Involved in GO:0071880 adenylate cyclase-activating adrenergic receptor signaling pathway
The following genes and proteins are central to adrenergic receptor signaling that activates adenylate cyclase and cAMP-dependent downstream responses.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB1 | Adrenergic receptor that couples to Gs and activates adenylate cyclase | Target for cardiac and neuronal studies of cAMP signaling [1,3] |
| ADRB2 | Adrenergic receptor that stimulates cAMP production | Model receptor for agonist-induced transcriptional activation |
| ADRB3 | Adrenergic receptor linked to metabolic and cAMP responses | Relevant to adrenergic drug effects and metabolic signaling [1,5] |
| GNAS | Gs alpha subunit that couples receptors to adenylate cyclase | Core transducer for adenylate cyclase activation |
| ADCY1 | Adenylate cyclase isoform that synthesizes cAMP | Enzyme node for cAMP-dependent outputs [1,4] |
| ADCY2 | Adenylate cyclase isoform contributing to cAMP production | Potential modifier of pathway strength |
| PRKACA | Catalytic subunit of PKA activated by cAMP | Effector kinase for downstream phosphorylation |
| CREB1 | Transcription factor phosphorylated in response to cAMP | Readout of pathway activation in pinealocytes and neurons |
| VIPR1 | VIP receptor that can activate adenylate cyclase | Comparative receptor in pineal and neuroendocrine studies |
| VIPR2 | VIP/PACAP receptor coupled to cAMP | Model for adenylate cyclase-activating GPCR signaling |
| ADCYAP1R1 | PACAP receptor that activates adenylate cyclase | Linked to antidepressant mechanisms and learning [6,7] |
| ADCYAP1 | PACAP ligand that activates adenylate cyclase pathways | Used to probe cAMP-dependent neuronal and endocrine responses [6,7] |
| TRPC1 | Ion channel implicated in secretion downstream of receptor activation | Studied in adrenal medullary chromaffin cells |
| TRPC4 | Ion channel contributing to secretion mechanisms | Relevant to PACAP and muscarine-evoked secretion |
| TRPC5 | Ion channel involved in chromaffin cell secretion | Focus of adrenal medullary studies |
| TRPC6 | Ion channel linked to receptor-evoked secretion | Experimental target in chromaffin cells |
| DRD2 | Dopamine receptor relevant to aripiprazole and prolactin biology | Indirect crosstalk with adrenergic/cAMP mechanisms |
| HTR2A | Serotonin receptor implicated in clozapine pharmacology | Network pharmacology node in cardiac arrest study |
How Is adenylate cyclase-activating adrenergic receptor signaling pathway Regulated?
Regulation of GO:0071880 occurs at multiple levels, including receptor availability, G protein coupling, and downstream cAMP turnover [1,4]. In pinealocytes, control of CREB phosphorylation is a regulated step that determines induction of melatonin synthesis, showing that the pathway is tuned at the level of transcription factor activation. PACAP and VIP receptors provide additional regulatory input to adenylate cyclase-activating pathways in neuroendocrine tissues, and their pharmacological and molecular characterization indicates that receptor subtype expression shapes the response [6,8]. Adrenergic agonist-induced transcriptional activity in immortalized suprachiasmatic nucleus cells further suggests that the pathway is subject to cell-type-specific regulation.
adenylate cyclase-activating adrenergic receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRB1 | Cardiac arrest risk with clozapine | Cardiomyocyte knockout or point mutation |
| ADRB2 | Adrenergic drug response and transcriptional activation | Neuronal cell overexpression or knockout |
| CREB1 | Melatonin synthesis and circadian output | Pinealocyte knock-in of phospho-mutant CREB1 |
| ADCYAP1R1 | Antidepressant action and learning | Neuronal knockout or overexpression [6,7] |
| TRPC5 | Adrenal medullary secretion | Chromaffin cell knockout |
Cardiac effects of psychiatric drugs
Network pharmacology and molecular docking studies of clozapine-induced cardiac arrest identify adrenergic and cAMP-related mechanisms among the pathways involved, linking GO:0071880 to drug-induced cardiac risk. This suggests that adrenergic receptor signaling that activates adenylate cyclase may modulate cardiac outcomes in patients receiving such medications.
Hyperprolactinemia and antipsychotic action
Aripiprazole has been explored for hyperprolactinemia using network pharmacology and molecular docking, with adrenergic and cAMP-related nodes contributing to the predicted mechanism. This connects GO:0071880 to endocrine and psychiatric disease biology.
Neuroendocrine and circadian dysfunction
Adrenergic agonists activate transcriptional activity in immortalized neuronal cells from the mouse suprachiasmatic nucleus, and cAMP-CREB signaling controls melatonin synthesis in pinealocytes [1,4]. These findings link GO:0071880 to circadian and neuroendocrine regulation, with potential relevance to sleep and mood disorders [1,4].
Learning and transmitter-related behavior
PACAP, which signals through adenylate cyclase-activating receptors, affects passive avoidance learning with involvement of transmitters, and PACAP receptors have been studied in antidepressant mechanisms [6,7]. This supports a role for adenylate cyclase-activating pathways in behavioral and cognitive processes [6,7].
From adenylate cyclase-activating adrenergic receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADRB1 alter cAMP-dependent transcription? | ADRB1 knockout in neuronal cells |
| Does a point mutation in CREB1 prevent melatonin synthesis? | CREB1 point-mutation knock-in in pinealocytes |
| Can tagged GNAS reveal receptor coupling dynamics? | Tagged knock-in of GNAS |
| Does ADCYAP1R1 overexpression enhance cAMP responses? | Overexpression in neuroendocrine cells [6,7] |
| Is TRPC5 required for PACAP-evoked secretion? | TRPC5 knockout in chromaffin cells |
| Does ADRB2 activation drive transcriptional programs? | ADRB2 overexpression or knockout in immortalized neurons |
How to Study the adenylate cyclase-activating adrenergic receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| cAMP assay | Intracellular cAMP levels | Receptor-mediated adenylate cyclase activation [1,4] |
| Phospho-CREB immunoblot | CREB phosphorylation | Downstream pathway activation in pinealocytes |
| RNA-seq | Transcriptional changes | Adrenergic agonist-induced gene programs |
| Network pharmacology | Drug-target-pathway networks | Mechanism of clozapine or aripiprazole effects [3,5] |
| Molecular docking | Predicted ligand-receptor interactions | Prioritizing adrenergic and related targets [3,5] |
| Pharmacological characterization | Receptor subtype function | VIP/PACAP receptor studies in pineal gland |
| Secretion assays | Hormone or transmitter release | Adrenal medullary chromaffin cell studies |
| Behavioral testing | Learning and memory outcomes | PACAP effects on passive avoidance |
Transcriptional reporters and RNA-seq
Adrenergic agonist-induced transcriptional activity can be measured in immortalized neuronal cells, and RNA-seq can define the gene programs downstream of GO:0071880. This approach links receptor activation to changes in gene expression.
cAMP and phospho-CREB assays
Because the pathway converges on cAMP and CREB phosphorylation, biochemical assays for cAMP and phospho-CREB are standard readouts. In pinealocytes, control of CREB phosphorylation is directly tied to melatonin synthesis, providing a physiological endpoint.
Pharmacological and molecular characterization
Pharmacological, molecular, and functional characterization of VIP/PACAP receptors in the rat pineal gland illustrates how receptor subtype contributions to adenylate cyclase activation can be dissected. Similar strategies apply to adrenergic receptors.
Network pharmacology and docking
Network pharmacology and molecular docking have been used to explore mechanisms of clozapine-induced cardiac arrest and aripiprazole in hyperprolactinemia, identifying adrenergic and cAMP-related nodes [3,5]. These methods help prioritize pathway components for experimental validation [3,5].
How CRISPR Can Be Used to Study GO:0071880 adenylate cyclase-activating adrenergic receptor signaling pathway
Knockout
CRISPR knockout of adrenergic receptors, GNAS, or adenylate cyclase isoforms can test whether they are required for cAMP production and downstream transcriptional or secretory outputs of GO:0071880 [1,4]. Knockout of TRPC channels in chromaffin cells can similarly test their role in receptor-evoked secretion.
Point Mutation
Point mutations can be introduced into CREB1 phosphorylation sites or receptor residues to dissect which molecular events are necessary for downstream effects such as melatonin synthesis. Such models help distinguish correlation from causation in pathway signaling.
Knock-in
Tagged knock-in of GNAS or adenylate cyclase can enable real-time tracking of pathway components and their interactions in living cells. Knock-in of reporter alleles can also provide sensitive readouts of pathway activation.
Overexpression
Overexpression of ADRB2 or ADCYAP1R1 can amplify cAMP responses and reveal gain-of-function phenotypes in neuronal or neuroendocrine cells [1,6,7]. This is useful for testing whether increased pathway activity is sufficient to drive downstream outputs [1,6].
How EDITGENE Supports adenylate cyclase-activating adrenergic receptor signaling pathway Research
Researchers studying adenylate cyclase-activating adrenergic receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in cAMP-dependent outputs, rather than merely correlated with them. EDITGENE provides the CRISPR tools and cell models required to move from association to mechanism in this pathway.
Contact EDITGENE today to design your custom CRISPR model for adenylate cyclase-activating adrenergic receptor signaling pathway research.
Frequently Asked Questions About adenylate cyclase-activating adrenergic receptor signaling pathway
What is GO:0071880?
GO:0071880 is the biological process adenylate cyclase-activating adrenergic receptor signaling pathway, in which an adrenergic receptor binds a ligand and activates adenylate cyclase to produce cAMP and regulate downstream cellular processes.
What genes are involved in adenylate cyclase-activating adrenergic receptor signaling pathway?
Key genes include ADRB1, ADRB2, ADRB3, GNAS, ADCY isoforms, PRKACA, and CREB1, with comparative contributions from PACAP/VIP receptors such as ADCYAP1R1 and VIPR2 [1,4,6,8].
What does adenylate cyclase-activating adrenergic receptor signaling pathway do?
It converts adrenergic ligand binding into cAMP production and downstream effects such as CREB phosphorylation, transcriptional changes, and secretion [1,4].
How is cAMP involved in adrenergic receptor signaling?
Adrenergic receptors activate adenylate cyclase, which synthesizes cAMP; cAMP then activates effectors including PKA and CREB to regulate cellular responses [1,4].
Which diseases are linked to adrenergic-cAMP signaling?
Studies link this pathway to cardiac effects of clozapine, hyperprolactinemia mechanisms of aripiprazole, and neuroendocrine or circadian biology [1,3,4,5].
How can I study GO:0071880 in the lab?
Common approaches include cAMP assays, phospho-CREB immunoblot, RNA-seq, pharmacological characterization, and network pharmacology or docking [1,3,4,5,8].
What CRISPR models are useful for this pathway?
Knockout, point mutation, knock-in, and overexpression models of adrenergic receptors, GNAS, adenylate cyclase, and CREB1 are useful for causal studies [1,4].
Is PACAP related to adenylate cyclase-activating adrenergic signaling?
PACAP signals through adenylate cyclase-activating receptors and has been studied in antidepressant mechanisms and learning, providing comparative insight into cAMP pathways [6,7].
What cell types are used to study this pathway?
Immortalized neuronal cells from the suprachiasmatic nucleus, pinealocytes, and adrenal medullary chromaffin cells are used in published studies [1,2,4].
Why is CREB important in this pathway?
CREB phosphorylation downstream of cAMP controls gene expression and physiological outputs such as melatonin synthesis in pinealocytes.
Conclusion
GO:0071880, adenylate cyclase-activating adrenergic receptor signaling pathway, is a well-defined biological process that links adrenergic ligand binding to cAMP production and downstream cellular regulation [1,4]. Its components are experimentally tractable, and published studies connect it to neuronal transcription, melatonin synthesis, adrenal secretion, and drug-related disease mechanisms [1,2,3,4,5]. CRISPR-based knockout, point mutation, knock-in, and overexpression models provide a direct route to test causality within this pathway [1,4].
References
- 1. Langiu M et al.. 2024. Adrenergic Agonists Activate Transcriptional Activity in Immortalized Neuronal Cells From the Mouse Suprachiasmatic Nucleus.. J Pineal Res 76(5):e12999 PMID: 39092782
- 2. Inoue M et al.. 2026. Muscarine, Pituitary Adenylate Cyclase Activating Polypeptide, and Angiotensin II-Evoked Secretion in Adrenal Medullary Chromaffin Cells With a Major Focus on TRPC Channels.. J Neurochem 170(5):e70460 PMID: 42138471
- 3. Chen X et al.. 2025. Network pharmacology and molecular docking to explore mechanisms of clozapine-induced cardiac arrest.. J Psychiatry Neurosci 50(1):E1-E10 PMID: 39753306
- 4. Maronde E et al.. 1997. Control of CREB phosphorylation and its role for induction of melatonin synthesis in rat pinealocytes.. Biol Cell 89(8):505-11 PMID: 9618900
- 5. Yang L et al.. 2024. Exploring the potential pharmacological mechanism of aripiprazole against hyperprolactinemia based on network pharmacology and molecular docking.. Schizophrenia (Heidelb) 10(1):105 PMID: 39511179
- 6. Reichenstein M et al.. 2008. Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action.. J Mol Neurosci 36(1-3):330-8 PMID: 18592413
- 7. Telegdy G et al.. 2000. The action of pituitary adenylate cyclase activating polypeptide (PACAP) on passive avoidance learning. The role of transmitters.. Brain Res 874(2):194-9 PMID: 10960604
- 8. Simonneaux V et al.. 1998. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.. Neuroscience 85(3):887-96 PMID: 9639281
